Aldoxorubicin: Phase Ib started

CytRx began an open-label, dose-escalation Phase Ib trial to evaluate 170, 250 and 350 mg/m 2 IV aldoxorubicin on day 1 of a 28-day cycle plus ifosfamide in up to 30 patients with locally advanced, un...